NCT02425683 is a Phase 2 clinical trial of Regorafenib in Colorectal Neoplasms, sponsored by US Oncology Research.

Who is sponsoring NCT02425683?

NCT02425683 is sponsored by US Oncology Research.

What drugs are being tested in NCT02425683?

Interventions in NCT02425683: Regorafenib.

What condition does NCT02425683 study?

NCT02425683 studies Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum.

Is NCT02425683 still recruiting?

NCT02425683 is currently terminated. Last updated 10 February 2020.

Last reviewed 2020-02-10 · How we verify

NCT02425683

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Terminated Phase 2 Last updated 10 February 2020

What this trial tests

Phase 2 trial testing Regorafenib in Colorectal Neoplasms in 24 participants. Terminated before completion.

Timeline

26 March 2015

Primary endpoint
21 September 2017

21 September 2017

Quick facts

Lead sponsor	US Oncology Research
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	26 March 2015
Primary completion	21 September 2017
Estimated completion	21 September 2017
Sites	1 location across United States

Drugs / interventions tested

Regorafenib — full drug profile →

Conditions studied

Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Adenocarcinoma of the Colon — all drugs for Adenocarcinoma of the Colon →
Adenocarcinoma of the Rectum — all drugs for Adenocarcinoma of the Rectum →

Sponsor

US Oncology Research — full company profile →

Who can join

18 and older, any sex, with Colorectal Neoplasms or Adenocarcinoma of the Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no further treatment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The role of tumor angiogenesis as a therapeutic target in colorectal cancer.
Battaglin F, Puccini A, Intini R, Schirripa M, et al · · 2018 · cited 48× · PMID 29338550 · DOI 10.1080/14737140.2018.1428092
Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.
Wu FT, Man S, Xu P, Chow A, et al · · 2016 · cited 44× · PMID 27651308 · DOI 10.1158/0008-5472.can-16-0888
Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.
Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. · · 2021 · cited 36× · PMID 34125494 · DOI 10.15252/emmm.201708253

Verify or expand the search:

Other trials of Regorafenib

Trials testing the same drug.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07392866 — A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellula · Phase 2, PHASE3 · not yet recruiting
NCT06820957 — Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has S · Phase 2, PHASE3 · active not recruiting
NCT07223567 — A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cance · Phase 2 · withdrawn
NCT07134205 — The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting

Other US Oncology Research trials

Trials by the same sponsor.

NCT04782687 — Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma · Phase 2 · active not recruiting
NCT02187991 — Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer · Phase 2 · completed
NCT02000882 — STAR Cape+BKM120 MBC With Brain Met · Phase 2 · completed
NCT00493870 — TAC Versus TC for Adjuvant Breast Cancer · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02425683 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by US Oncology Research
Last refreshed: 10 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02425683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing